Background Antineoplastic drugs for cancer are often associated with adverse events, which influence patients' physical health, quality of life and survival. However, the modelling of adverse events in cost-effectiveness analyses of antineoplastic drugs has not been examined. Aims This article reviews published economic evaluations that include a calculated cost for adverse events of antineoplastic drugs. The aim is to identify how existing models manage four issues specific to antineoplastic drug adverse events: the selection of adverse events for inclusion in models, the influence of dose modifications on drug quantity and survival outcomes, the influence of adverse events on quality of life and the consideration of multiple simultaneous or recurring adverse events. Methods A systematic literature search was conducted using MESH headings and key words in multiple electronic databases, covering the years 1999-2009. Inclusion criteria for eligibility were papers covering a population of adults with solid tumour cancers, the inclusion of at least one adverse event and the resource use and/or costs of adverse event treatment.
• Current models of antineoplastic drug cost effectiveness may underestimate the incidence, cost and flow-on effects of adverse events.
• Decision makers should examine whether issues such as the selection of adverse events for inclusion, the implications of dose modifications, the impact of adverse events on quality of life, and the potential for multiple adverse events have been considered in models of antineoplastic drug cost effectiveness.
• Models that address all of these issues relating to adverse events are feasible, and would allow decision makers to make better informed decisions about the cost effectiveness of antineoplastic treatments.
adverse events. More than 750 adverse events are listed in the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), which is used to define and grade the seriousness of adverse events associated with cancer treatments [2] . Adverse events have been estimated to contribute up to 60 % of the total cost of chemotherapy [3] . Willingness to pay for cancer treatments in the community is high, owing to a widespread public perception of cancer as a hidden and feared disease [4, 5] . This may lead to a 'treat at all costs' attitude with little consideration given to the economic impacts of these treatments [4, 5] . Economic evaluation is increasingly used to provide information to decision makers in the healthcare system about the relative value of alternative treatment strategies [4] . While such evaluations can be conducted as part of a clinical trial, economic modelling is often used to estimate costs and benefits in the longer term and to take into account different endpoints and comparators [6] .
Economic evaluation requires consideration of both the costs and benefits of a treatment, with data used to populate these costs and benefits in the model referred to as inputs. Typically, antineoplastic drugs include three broad cost components-purchasing the antineoplastic products, time and resources for administration of the drugs, and managing adverse events. On the benefit side, disease outcomes such as cancer progression and survival are commonly measured, with quality-of-life measurement required for cost utility analyses. Inputs to economic evaluations for antineoplastic drug outcomes are often readily available through clinical trials, while product purchase costs can be obtained from pricing lists. Less information is available estimating the costs of administration [7] and adverse events related to antineoplastic drugs [8] .
There are a number of issues that are specific to the adverse events of antineoplastic drugs that need to be considered in economic evaluations.
Adverse Event Selection
The inclusion of adverse events in models of antineoplastic drugs is important as these events can influence both sides of the economic evaluation equation. Many economic evaluations of antineoplastic drugs are conducted for the purpose of reimbursement. In this case, awareness of the cost-effectiveness threshold is important, as well as the impact of model structure and inputs. The equal treatment of both arms is critical, and all relevant costs and consequences need to be accounted for so that total costs can be considered.
Dose Modifications
As well as incurring a cost to manage the adverse event itself, the experience of an adverse event changes the way a patient receives antineoplastic therapy. In many cases, when a patient experiences an adverse event, their drug dose is either delayed or the dose reduced until they have recovered from the adverse event [9] . The antineoplastic treatment may then continue at the reduced dose to lessen the chance of the adverse event re-occurring [9] . This influences the total amount of antineoplastic drug the patient receives [10] , and therefore the amount of product purchased.
The amount of an antineoplastic drug received by a patient can also impact on the outcomes of their treatment. The relative dose intensity of chemotherapy is the ratio of the delivered chemotherapy to the planned chemotherapy dose over a specified period of time [11] . There is evidence that patients who receive a relative dose intensity of less than 85 % have significant reductions in survival [10, [12] [13] [14] [15] [16] [17] [18] . Retrospective studies have found that up to 56 % of people have a relative dose intensity less than 85 % because of dose adjustments in response to adverse events [19] .
Adverse Events and Quality Of Life
While adverse events differ between individuals, almost all patients taking antineoplastic drugs will experience at least one adverse event [20] . Many patients report adverse events to be very distressing, with quality of life significantly impacted [21] [22] [23] . It is therefore important to consider that there may be additional utility decrements associated with having an adverse event, in addition to those already associated with having cancer and receiving antineoplastic therapy.
Multiple Adverse Events
The final consideration when including antineoplastic drug-related adverse events in economic evaluation models is that of multiple events. Patients may experience multiple adverse events in two ways-either the same event occurring multiple times over a course of antineoplastic therapy or different adverse events happening simultaneously. If a patient experiences the same event repeatedly, the management of the adverse event in terms of prevention, treatment and dose modifications may change, resulting in different costs and outcomes for the model [9] . The occurrence of more than one adverse event at the same time impacts on the management of each adverse event in terms of treatment, prevention and antineoplastic drug dose [9] , and may also change the quality-of-life impact of an event.
While there are generic guidelines for the development of economic evaluation models [24] , these do not consider cancer-specific issues that may bias results [8] . A review of methods used for a cost-effectiveness analysis of cancer treatments found common problems in the areas of defining the decision problem, choosing the health outcomes, modelling effectiveness of different types of treatment, modelling quality of life, modelling resource use including adverse events, discounting and assessing uncertainty [8] . However, the authors are unaware of any published reviews of the modelling techniques used specifically for evaluating the costs and consequences of adverse events associated with antineoplastic drugs.
Adverse events have the potential to have a significant impact on models of antineoplastic drug cost effectiveness through not only the cost of managing the event itself, but also in terms of the quantity of antineoplastic products used, patient quality of life and survival outcomes. It is therefore important that adverse events be taken into account when conducting economic evaluations of antineoplastic drugs to ensure accurate estimates of cost effectiveness are obtained.
Aim
This article reviews published economic evaluations that include a method for determining resource use and/or have a method for calculating a cost for adverse events of antineoplastic drugs, to identify how these existing models manage potentially problematic areas specific to antineoplastic drug adverse events. The primary areas of interest are model structure and inputs related to:
• The selection of adverse events for inclusion in models • The influence of dose modifications -on antineoplastic drug product quantity -on survival outcomes
• The influence of adverse events on quality of life • The influence of multiple adverse events, including -the same event occurring multiple times during a course of antineoplastic drug therapy -multiple events occurring at the same point in time.
Methods
A systematic literature search was conducted to identify relevant papers reporting research involving modelling the cost of antineoplastic drug adverse events. Inclusion criteria for eligibility were papers covering a population of adults with solid tumour cancers, the inclusion of at least one antineoplastic drug-related adverse event, the resource use and/or calculated costs of adverse event treatment, as well as a stated method or assumptions for determining the resource use and/or costs of adverse events. Studies were excluded if they presented clinical guidelines or were not original research. Conference abstracts were excluded as the information within them was too limited for the purposes of this review.
The following electronic databases were searched to identify relevant articles published in English from January 1999 to September 2009: MEDLINE, EMBASE, PubMed, EBM Reviews, CINAHL, Cochrane Library, Business Source Premier, Academic Search Premier, Econlit, NHS EED, York HTA, ASCO and the TUFTS CEA Registry. A search strategy was developed for each database using MESH headings (neoplasms, drug therapy, antineoplastic agents, drug toxicity, adverse effect, costs and cost analysis, cost benefit analysis, economics, length of stay, health resources) and relevant keywords (carcinoma, chemotherapy, adverse event, adverse reaction, toxicity, side effect, complication, undesired effect, cost, resource, hospitalisation). The search strategies for MEDLINE, NHS EED and York HTA are provided in Electronic Supplementary Material.
Titles and abstracts of the retrieved citations were screened to identify potentially eligible papers. Final assessment of eligibility was based on a review of full text articles. Additional papers identified from personal files and the reference lists of included papers were hand searched. Assessment of eligibility was completed by one reviewer for all citations. For studies where eligibility was unclear, a second opinion was sought.
Study quality was assessed for all eligible articles using the checklist developed by Graves et al. [25] . This checklist covers four aspects of study quality, primarily related to costing: costing issues, methods to determine quantities of resources used, valuing of resources and data reporting [25, 26] . Papers were scored from 0 to 12 based on the number of criteria that were met.
Data extraction was completed by one reviewer for all articles, using the NHS EED annotated abstract template (http://www.crd.york.ac.uk/CRDWeb/AboutNHSEED.asp). For the primary areas of interest, information was extracted on how adverse events were identified for inclusion in the model, whether or not dose modifications were considered, whether the quality-of-life impact of adverse events were included, and whether multiple adverse events (either over time or consecutively) were considered.
Results
The search yielded 4,985 citations, with 26 eligible articles identified that described the use of economic models including methods or assumptions for resource use and/or the costs of adverse events associated with antineoplastic drugs. Figure 1 presents a flow chart of study selection. Tables 1, 2 , 3, 4, 5 and 6 provide the details of each study included in the review. The papers were either designed to determine the costs and effectiveness of antineoplastic therapy (n = 16) or the costs of a specific treatment for an adverse event (n = 10). The aims of these types of studies result in different methodologies and complexities. However, as both provide different and important approaches to answering the questions relevant to this review, it was decided to include both study types, but to consider them separately. Table 7 summarises the characteristics of the included studies. Generally studies were of moderate quality, with a mean Graves score of seven and a range of 3-10 ( Tables 1,  2 , 3, 4, 5 and 6). Six studies [19, [27] [28] [29] [30] [31] included multiple cancer types, with the remaining focussing on a specific cancer, the most common being breast cancer (12 studies). Over half of the studies were based in the USA, with no studies from Australia or New Zealand. Table 8 shows the modelling methods used by the included studies. Cost-effectiveness analyses of antineoplastic treatments primarily used Markov models, while decision trees were used in studies of the costs of treating adverse events. Eighty five percent of studies used a cost-effectiveness or cost-consequence analysis. The perspective taken was classified according to each study's stated methods. Based on the costs included in the models, the three studies with an unspecified perspective appear to have used a societal perspective in two cases [32, 33] and a hospital perspective in the other case [34] .
General Model Design

Adverse Event Selection
The 26 studies examined 21 different adverse events. Eleven studies [27] [28] [29] [30] [31] [32] [35] [36] [37] [38] [39] , mostly adverse event treatment studies, considered a single adverse event. Of the remaining studies, nine [33, 34, [40] [41] [42] [43] [44] [45] [46] included between two and five adverse events, while six [47] [48] [49] [50] [51] [52] examined more than five, with 15 being the most adverse events costed in a single study [52] .
A number of studies (n = 6) did not specify on what basis specific adverse events were selected for inclusion in the models. Five studies [33, 38, [41] [42] [43] cited as a reason the presence of a significant difference (based on various definitions) in incidence rates of the event between different treatment arms in the literature. Other reasons included a significant incidence in any treatment arm (usually at the 1 or 5 % level) [41, 42] , potential to impact on cost [45, 47, 49, 52] or the potential to impact on patient quality of life [51] . Twenty studies included any grade of the event, while six [34, 41, 45, 47, 49, 52] restricted inclusion to only grade III/IV events (high-cost/low-volume events) or those resulting in hospitalisation.
Dose Modifications
The impact of adverse events on the individual's dose of antineoplastic therapy was specifically examined in five studies [41-43, 49, 52] , all of which were evaluations of cost and effectiveness of antineoplastic drugs, with access to primary data regarding dose modifications during treatment. This allowed investigators to include the actual dose received in the models. An additional five antineoplastic drug evaluations [39, 44, 45, 47, 51] indirectly examined the impact of dose modifications on total dose received by using the average dose given from clinical trials, which should have included patients who had dose reductions or delays. The remaining six antineoplastic drug evaluations and all of the adverse event treatment studies assumed patients received 100 % of the planned dose, regardless of the experience of adverse events. In one study, this was justified as being a conservative estimate of antineoplastic therapy cost [48] .
While early cessation of antineoplastic therapy was sometimes considered in terms of the amount of drug delivered, the impact of dose reduction and delays on survival was not. Two studies, both based on the same neutropenia treatment model, included the scenario where improved adverse event management resulted in lower probability of receiving less than 85 % of relative dose intensity, with resulting long-term survival benefits [36, 37] . In this model, the impact of relative dose intensity on long-term survival was determined using a Markov process in which the patient was followed until death [36, 37] . [36, 37] . Inputs for the proportion of patients who received less than 85 % RDI, and the associated relative risk of death for those with an RDI \85 % (compared with those with over 85 %) were based on literature [36, 37] .
Adverse Events and Quality of Life
Measurements of quality of life for various states of cancer and cancer treatment were used in 18 of the 26 studies (six adverse event treatment studies and 12 antineoplastic drug evaluations, see Tables 1, 2 , 3, 4, 5 and 6). Thirteen of these studies included a utility decrement associated with antineoplastic drug adverse events (six adverse event treatment studies and seven antineoplastic drug evaluations), and thus had the potential to calculate a cost per quality-adjusted life-year (QALY). Some of these estimates included unique decrements for adverse events at different grades, or required different treatment, such as hospitalisation compared with out-patient management, but others included a common estimate for the adverse event that was not related to grade or treatment. Utility estimates for cancer and antineoplastic therapy health states were usually obtained from previous published studies in the same or similar clinical areas. In contrast a number of utilities for adverse event health states were based on assumptions, rather than empirical evidence [27, 34, 46] . For example, Lidgren et al. [46] simply reduced the utility value by 50 % for 6 months in those experiencing symptomatic heart failure.
Multiple Adverse Events
While most models (n = 14) allowed for people experiencing the same event multiple times during a period of antineoplastic therapy, only two studies [36, 37] (both adverse event treatment evaluations) specifically considered multiple events over time. These studies, both based on the same febrile neutropenia treatment model, added the cost of subsequent care for febrile neutropenia to the cost of initial hospitalisation. This was based on the assumption that having experienced one episode of febrile neutropenia, an individual is at increased risk of developing febrile neutropenia in the future [36, 37] .
In two studies, models were developed that allowed for multiple events to occur at the same time, (one antineoplastic drug evaluation and one adverse event treatment evaluation). Touchette et al. [40] modelled febrile neutropenia, anaemia and thrombocytopenia, and allowed for any combination of the three to be experienced in each cycle of a Markov model. The costs and incidences of adverse events were averaged using a simple decision tree prior to being entered into the model [40] . However, the incidence and cost of each adverse event do not appear to differ based on the combination of events experienced. Delea et al. [48] created a model in which health states were characterised by all combinations of adverse events. The model included endometrial cancer, venous thromboembolism, myocardial infarction, unstable angina, heart failure, hip fracture, other fractures, arthralgia and hypercholesterolemia [48] . Again, whilst the model allows for multiple adverse events to be experienced within a cycle, a simple additive model was used and as such the incidence and cost of each adverse event do not appear to have changed with the experience of multiple events.
Overall
No studies included all of the concepts of interest in their models; three studies included none of the concepts of interest in their models [31, 32, 35] . Most commonly included were the potential for an individual to experience the same event multiple times during the time horizon, and the impact of adverse events on patient quality of life.
The two studies that included the most factors were those by Danova [36] and Lui [37] . Both studies used the same model for the management of neutropenia using granulocyte colony-stimulating factors in women with breast cancer [36, 37] . The model includes the impact of dose modifications on survival, the impact of neutropenia and its treatment on quality of life, and the potential for one episode of neutropenia to increase risk of multiple future episodes of neutropenia [36, 37] . As this was a model of neutropenia management, the cost of chemotherapy was assumed to be the same in both arms [36, 37] . This means that the influence of dose modifications on the total cost of chemotherapy is not accounted for, and may bias the results. However, this model provides an example of how many of the important components of antineoplastic drugrelated adverse events can be incorporated into a costeffectiveness model. 
Discussion
This review of the literature identified two types of economic studies that considered the costs of antineoplastic drug-related adverse events: cost-effectiveness analyses of antineoplastic treatments and assessments of the costs or cost effectiveness of treatments for antineoplastic drugrelated adverse events. Whilst there was variation across the studies in terms of methods used, a number of elements were consistent. Most studies were cost-effectiveness analyses undertaken from a healthcare system or hospital perspective, with only direct costs included. Selection of adverse events for inclusion in models was based on incidence, cost or impact on quality of life. A high proportion of studies of breast cancer were included in the review. This may reflect both a high incidence of this cancer generally, as well as a number of advances in systemic treatments made over the last 10 years, many of which would have required economic evaluation for registration.
The adverse events related to antineoplastic therapy are complex, and their consideration in economic evaluation is vital to ensuring accurate models are developed. Current modelling techniques have a number of limitations that restrict our understanding of the true impact of adverse events on antineoplastic therapy cost effectiveness. The results of this review suggest that many published models that include information regarding adverse events associated with antineoplastic therapy underestimate the incidence, costs and flow-on effects of adverse events.
In considering the issues of adverse event selection, dose modifications, quality of life and multiple adverse events, the results of this review provide an opportunity to present recommendations for the modelling of adverse events in antineoplastic therapy cost-effectiveness studies. These recommendations have been presented as broad statements, as they are likely to be new considerations for modellers, and to require additional complexity and data in the models. However, they provide a starting point for the inclusion of all relevant impacts of adverse events on the costs and outcomes of antineoplastic drug therapy.
Existing Comparisons of Adverse Event Models in Antineoplastic Therapy Economic Evaluations
Existing reviews of adverse events in economic evaluations of antineoplastic therapy report similar results to those of this review. An NHS Health Technology Assessment reviewed economic evidence from four studies of topotecan, doxorubicin and paclitaxel for ovarian cancer [53] . The four eligible studies included in the review used similar clinical evidence in their estimates of chemotherapy effectiveness, supplemented with estimates of resource use and costs from sources such as expert opinion, patient questionnaires and practice audits [53] . The review concluded that different model assumptions about adverse event management had the potential to both over-estimate costs through the inclusion of specialised treatment of high-volume/low-cost events, and under-estimate chemotherapy adverse event incidence and costs through assumptions regarding multiple hospital admissions per cycle [53] .
An economic evaluation of erythropoietin agents for the treatment of chemotherapy-related anaemia provided estimates of the cost of anaemia when treated using a specified clinical pathway, modelled in a variety of ways and by a variety of people [54] . The different models produced marked variations in results, with a range of between £190,000 and £9,000 per QALY gained [54] . This variation in results highlights the influence that model design and assumptions can have on the outcomes of economic evaluation.
Finally, a number of cost-of-illness studies have examined the costs associated with antineoplastic drug-induced neutropenia, diarrhoea, anaemia and infusion reactions. Many of these used methods such as retrospective surveys or cohort record reviews to build a bottom-up estimate of the costs of specific adverse events [55] [56] [57] [58] [59] [60] [61] . Alternatively, some studies have used the information available from hospital and health insurance databases to determine the additional cost of healthcare attributable to treating a specific adverse event [62, 63] . Again, different model inputs resulted in significant variation in outcomes.
Adverse Event Selection
The selection criteria used to identify which adverse events to include in models may lead to an under-estimation of the base rate of adverse events. While the inclusion of only events with rates that differ between arms may not have an impact on the incremental cost-effectiveness ratio for particular antineoplastic drug alternatives, the overall cost of adverse events (and therefore its impact on the relevant budget) may be higher than that implied by the results. This influences whether the alternative interventions are considered cost effective at an acceptable threshold level. The importance of this will depend on the decision-making context that the evaluation is considered within.
Similarly, adverse events that are considered to be low cost or low severity may be excluded from the analysis. While a low incidence of adverse events may not influence cost effectiveness, high rates may have a significant impact on overall costs. This pattern of high incidence of lowgrade events can be seen in the new class of biologically targeted agents such as cetuximab for colorectal cancer. The pivotal study of cetuximab found 88 % of patients experienced a rash, including 76.8 % at the less serious grade I or II [64] . The economic analysis of this study excluded any adverse events less than grade III severity, as they were not thought to contribute significantly to resource use, despite occurring at any grade in only 16 % of individuals in the control arm [65] .
A non-significant difference in incidence between treatment arms for a specific adverse event does not necessarily indicate that there is no difference in global adverse event profiles between treatment arms in terms of the overall toxicity profile. By assuming conditional independence of the frequency of events, the potential for the sum of adverse events to differ between treatments is removed.
The inclusion of all relevant adverse events in models of antineoplastic therapy cost effectiveness is consistent with recommendations for the modelling of adverse effects for all health interventions [66, 67] . However, including all adverse events will require additional complexity in the model, and additional data to populate these components of the model. The use of Markov modelling techniques may provide a way to address this additional complexity [6] , and clinical trials would be the most likely source of additional information about the costs and consequences of adverse events. Further work is required to identify how the inclusion of all adverse events will impact results.
Recommendation: All relevant adverse events that are associated with antineoplastic drug treatment should be included in models of antineoplastic therapy cost effectiveness.
Dose Modifications
While some studies did consider the impact that dose modifications would have on the total dose of antineoplastic drugs received, many assumed all patients received 100 % of the recommended dose. In the context of a costeffectiveness evaluation, this would result in an overestimation of the costs, as some cost savings are ignored. In the area of cancer treatments, where new antineoplastic drugs are increasingly expensive, the cost of purchasing the drugs may be a significant contributor to costs, and therefore overall cost effectiveness. Intravenous treatments may have the additional complexity of wastage, as once a vial is opened it often must be used immediately or discarded. When a patient is on a reduced dose they may not receive the whole vial, but costs in the model will still need to reflect that a full vial has been used.
Clinical trial reports may provide details of the dose modifications and drug wastage during the trial. Information on planned dose, dose dispensed, dose received and reasons for dose modifications would be ideal for economic modelling. Where this information is not available, data from observational studies, such as information regarding the frequency of dose modifications, may be used to provide inputs to the model regarding the incidence of dose modifications. The potential cost savings associated with dose modifications can be estimated using the input price and incorporated into the estimates of product cost per treatment arm. Practice guidelines for the administration of antineoplastic drugs may provide some guidance to the modelling of product wastage.
Recommendation: The cost savings resulting from dose modifications due to adverse events should be accounted for in models of antineoplastic therapy cost effectiveness.
Only two studies considered the impact of dose modifications on survival. With survival often the primary outcome of effectiveness in cost-effectiveness studies, changes to it as a result of adverse events and dose reductions could affect the cost-effectiveness ratio, particularly if adverse events occur unevenly across treatment arms. As identified in this review, many economic evaluations of the cost effectiveness of antineoplastic therapy select adverse events for inclusion on the basis of there being a significant difference in incidence between treatments.
It is interesting that although there is a body of literature that examines the cost effectiveness of treatments for neutropenia in relation to their ability to maintain chemotherapy dose intensity [68] , there appears to be little transfer of this information into models of antineoplastic drug cost effectiveness, despite many of these models including neutropenia and the costs of its management.
There is relatively little evidence available for the influence of dose modifications on the effectiveness of specific antineoplastic drug treatments. This makes inclusion of these outcomes within the model difficult, as no data are available to populate the model. Economic models based on the results of a clinical trial that has followed patients to death will have implicitly considered the impact of dose modifications on survival. However, where followup is not complete or data are insufficient, the growing body of evidence across a range of chemotherapy treatments that receiving less chemotherapy reduces efficacy could be used within a sensitivity analysis of the estimated antineoplastic drug efficacy. This would allow the potential impact of uncertainty around the estimates of antineoplastic drug efficacy to be tested.
Recommendation: The impact of dose modifications due to adverse events on the outcomes of antineoplastic therapy should be considered and included in the sensitivity analysis of models of cost effectiveness.
Adverse Events and Quality of Life
The impact of cancer and antineoplastic therapy on quality of life is generally well considered in cost-effectiveness studies of antineoplastic drugs and new adverse event treatments. It is less common for the additional utility decrements associated with adverse events to be included, and these are often difficult to identify [69] . Part of the difficulty in including additional utility decrements (or improvements) associated with adverse events is how these should be considered in relation to the quality-of-life impacts of having cancer and undergoing antineoplastic drug therapy. While there are studies that have estimated specific utility decrements for adverse events independent of treatment [70] , in many cases the decrement associated with antineoplastic treatment may include a component related to adverse events. If this was the case, the addition of a decrement associated with an adverse event may lead to double counting [8] . It is therefore important that the original source of utility scores and the basis for the applied utility weights for both antineoplastic drugs and adverse events be understood before they are incorporated into an economic evaluation. In cases where adequate evidence to populate the specific utility decrements associated with adverse events are not available, utility measures for the experience of cancer and antineoplastic therapy that include the impact of adverse events should be sought.
Recommendation: The impact of adverse events on quality of life should be considered, and included in models of antineoplastic therapy cost effectiveness where adequate evidence to populate these components is available.
Multiple Adverse Events
As the usual sources of information about the incidence of adverse events, clinical trials report events separately and very rarely provide information about patterns of multiple adverse events. Thus, it is not surprising that models of antineoplastic therapy include each adverse event as an independent event. However, this is not reflective of real life. Multiple simultaneous adverse events are complex to model. It is often unclear which adverse event has resulted in which resource use (e.g. hospitalisation) or outcomes (e.g. reduced quality of life), and therefore the impact on cost effectiveness is difficult to gauge. The use of clinical trial data to examine patterns of multiple adverse events would provide an ideal resource for the modelling of multiple adverse events.
In relation to the influence of multiple events on utility, there has been significant interest in developing quantitative methods to account for co-morbidities when assessing health interventions [71] . In studies of cancer, adverse events are commonly considered individually; however, the high prevalence of simultaneous adverse events is increasingly recognised as important [72] . Whilst direct elicitation of the utility of these simultaneous events through techniques such as standard gamble and time trade-off is possible, the time, resources and respondent burden to collect utilities for more than a simultaneous event make conducting these assessments impractical [72] . Modelling approaches have therefore been investigated. The original additive approach to modelling combined utilities has been identified as overly simplistic, and techniques such as multiplicative and minimum modelling are now being studied and used [71, 72] .
Recommendation: Further research is required to allow the consideration of concurrent or consecutive multiple adverse events in models of antineoplastic therapy cost effectiveness.
Limitations of the Review
Whilst a systematic review of the literature was undertaken, there may be published economic models incorporating antineoplastic drug-related adverse events that were missed. The relatively small proportion of economic evaluations of antineoplastic drugs that were eligible for inclusion in the review appears to be a factor of the inclusion criteria requiring papers to present the methods for determining the resource use and/or cost of adverse events. The exclusion of those papers that simply report a cost without justification allows this review to focus on the methods used to include adverse events, but may result in it not being representative of all studies of antineoplastic drug cost effectiveness.
In addition, the exclusion of papers in languages other than English and conference abstracts may have biased the types of models that were included. Similarly, given that many economic evaluations are conducted for the purpose of policy decision making, there may be economic evaluations of antineoplastic agents that have been developed, but are not available in the peer-reviewed economic literature. These evaluations may differ systematically from those identified in this review, which may have biased the results.
A final potential limitation of the search strategy is that it identified two distinct types of economic evaluationsthose assessing the cost effectiveness of antineoplastic drugs, and those assessing the cost effectiveness of adverse event treatments. While both of these are appropriate to answer the questions posed by this review, separate search strategies may have resulted in more efficient identification of eligible papers in these two areas.
For many of the economic evaluations identified, particularly those assessing the cost effectiveness of antineoplastic drugs, the costs of adverse events were not the primary aim of the analysis. Conducting an economic evaluation is a difficult and time-consuming task, the aim of which is to provide information to decision makers.
Despite model builders' best efforts, the results of analysis are not designed to represent real life, but rather to provide information about the likely outcomes of a decision. This means that while there may be many aspects of the disease pathway, treatment choices, and patient characteristics that may influence the outcomes of a decision, they cannot all be incorporated into a model. It may be that for some of the models included in this review detailed modelling of adverse events was a lower priority than evaluations of other areas of the treatment pathway.
Conclusion
A number of components are important to the rigorous modelling of antineoplastic drug adverse events, including the selection of all relevant events, the impact of adverse events on antineoplastic drug dose, cancer outcomes and quality of life, and the consideration of multiple adverse events. This literature review systematically searched for all relevant articles that included adverse events in a model of costs and consequences of antineoplastic drugs. There were no models that incorporated all of the components discussed above. Two models addressed all but one of the issues, and these models provide an indication of how adverse events can be incorporated into economic evaluations in a rigorous way. Given that there were at least two examples of papers that considered each issue in their model development, it would appear that it is possible to build models of antineoplastic drug adverse events that consider all of these issues.
The adverse events related to antineoplastic therapy are complex; however, their consideration in economic evaluation is vital to ensuring accurate models are developed. Current modelling techniques have a number of limitations, which restrict our understanding of the true impact of adverse events on antineoplastic drug cost effectiveness, and it appears that many published models may underestimate the incidence, cost and flow-on effects of adverse events.
Rigorous modelling of antineoplastic drug adverse events will require the development of more complex models and the availability of additional data. Clinical trials are in a unique position to collect data on many aspects of antineoplastic drug adverse events. However, the inclusion of questions relating to economic evaluation needs to be considered in the study design phase. In the absence of trial data, or for information relating to the experience of antineoplastic drug adverse events outside the trial setting, data from observational or administrative datasets can contribute to economic evaluations. Again, careful consideration of the data available, the economic question being posed and the implications of using observational data is required.
Given that modelling adverse events with appropriate consideration of the inclusion of all events, dose modifications, quality of life and multiple events appears feasible, future models of antineoplastic drug adverse events should consider these issues.
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